<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523639</url>
  </required_header>
  <id_info>
    <org_study_id>G-LUCAS</org_study_id>
    <secondary_id>200084-610</secondary_id>
    <secondary_id>2011-001010-34</secondary_id>
    <nct_id>NCT01523639</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis</brief_title>
  <acronym>G-LUCAS</acronym>
  <official_title>A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type, Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Gesellschaft mbH, Austria</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter randomized, placebo-controlled phase II study will enroll 132 first-line
      palliative treated subjects with metastatic KRAS wild type CRC. Subjects with histologically
      confirmed, KRAS wild-type CRC without previous chemo-therapy for metastatic disease will be
      screened for this study.

      Approximately 10 sites in Austria will participate in the study. Subjects will be randomized
      in a ratio of 1:1 into two groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter randomized, placebo-controlled phase II study will enroll 132 first-line
      palliative treated subjects with metastatic KRAS wild type CRC.

      Wild-type KRAS is required for study entry. Further target-related parameters, based on
      current scientific knowledge may be assessed.

      Subjects are randomized to Arm A or Arm B Arm A: FOLFIRI in combination with cetuximab and
      metformin Arm B: FOLFIRI in combination with cetuximab and placebo

      A liver biopsy of hepatic metastasis and normal liver tissue is planned before the first
      cycle and at the end of treatment; with regard to the primary study objective, these subjects
      are evaluable.

      Both efficacy and safety data will be collected. The investigators will assess response to
      treatment every 8 weeks based on imaging.

      Following permanent treatment cessation, subjects will be followed-up for survival.

      One interim analysis for futility (54 evaluable patients) and in addition two safety analysis
      for evaluation of reported adverse events between the two treatment groups will be performed
      at two different timepoints (20 evaluable patients/54 evaluable patients).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013.
    ABCSG guaranteed completed treatment period for ethical reasons.
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the chemotherapy-associated steatosis</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Reduction in the chemotherapy-associated steatosis, as assessed by the steatosis subcore of NAFLD activity score (NAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 30 months</time_frame>
    <description>PFS will be evaluated after final study visits. Subjects who terminate the study before their scheduled final study visits will be censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 30 months</time_frame>
    <description>OS will be evaluated after final study visits. Subjects who terminate the study before their scheduled final study visits will be censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment of all randomized subjects with at least one administration of study treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>All subjects who received at least one dose of IMP. Additional safety analyses of reported AEs will be performed after the evaluation of 20 and 54 patients (between the 2 treatment groups) at the time of interim analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occured Adverse Events of all randomized subjects with at least one administration of study treatment</measure>
    <time_frame>up to 30 months</time_frame>
    <description>All subjects who received at least one dose of IMP. Additional safety analyses of reported AEs will be performed after the evaluation of 20 and 54 patients (between the 2 treatment groups) at the time of interim analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (CR/PR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Objective response rate (CR/PR), as assessed by RECIST criteria, version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in chemo-therapy associated steatohepatitis (CASH)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Reduction in chemo-therapy associated steatohepatitis (CASH) as assessed by NAS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFIRI + cetuximab + metformin every 2 weeks for 12 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>FOLFIRI + cetuximab + placebo every 2 weeks for 12 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin/Placebo</intervention_name>
    <description>The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity â‰¥ 2 due to IMP occurs.
Duration of treatment: 24 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Male or female &gt;= 18 years of age

          -  Diagnosis of histologically confirmed, KRAS &quot;wild-type&quot; adenocarcinoma of the colon or
             rectum

          -  Non-resectable metastatic colorectal carcinoma

          -  Either presence of at least one liver lesion measurable unidimensionally by CT scan or
             MRI or at least one resectable liver metastasis with non-resectable extrahepatic
             disease (as assessed within 3 weeks prior to randomisation)

          -  Subjects scheduled to receive cetuximab and FOLFIRI

          -  ECOG performance status of 0 - 1 at study entry

          -  Leukocytes &gt;= 3.0 x 10^9/L and neutrophils &gt;= 1.5 x 10^9/L, platelets &gt;= 100 x 10^9/L,
             and hemoglobin &gt;= 8 g/dL

          -  Bilirubin &lt;= 1.5 x ULN

          -  ASAT and ALAT &lt;= 5 x ULN

        Exclusion Criteria:

          -  Brain metastasis (if suspected, brain scan indicated)

          -  Previous chemotherapy for the currently existing metastatic disease

          -  Known or newly diagnosed diabetes

          -  Patients with ACS within the last three months

          -  Stage 3 or 4 heart failure defined according to the NYHA criteria

          -  Uncontrolled angina

          -  Contraindications to metformin (renal impairment [eGFR &lt;45 mL/min/1.73m^2], known
             hypersensitivity to metformin, acute illness [dehydration, severe infection, shock,
             acute cardiac failure]), and suspected tissue hypoxia

          -  Surgery (excl. diagnostic biopsy, central venous catheter) or irradiation within 2
             weeks prior to study entry defined as given written informed consent

          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
             indicated in the study protocol

          -  Administration of any investigational agent(s) within 4 weeks prior to study entry,

          -  Previous exposure to EGFR-pathway targeting therapy

          -  Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease

          -  Known grade 3 or 4 allergic reaction to any of the components of the treatment

          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
             the cervix. (Subjects with a previous malignancy but without evidence of disease for
             &gt;= 5 years will be allowed to enter the trial)

          -  Pregnancy or lactation

          -  Inadequate contraception (male or female patients) if of childbearing or procreative
             potential

          -  Known drug abuse/ alcohol abuse

          -  Legal incapacity or limited contractual capacity Medical or psychological condition
             which in the opinion of the investigator would not permit the patient to complete the
             study or sign meaningful informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birgit Gruenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Graz, Oncology</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, Internal Medicine</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital St. Vinzenz</name>
      <address>
        <city>Zams</city>
        <state>Tyrol</state>
        <zip>6511</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital BHS Ried</name>
      <address>
        <city>Ried</city>
        <state>Upper Austria</state>
        <zip>4910</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH BHB Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Univ. Vienna, General Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH St. Josef KH</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.abcsg.at</url>
    <description>Click here for more information about this study: open studies</description>
  </link>
  <reference>
    <citation>Colucci G, Maiello E, Leo S, Giuliani F, Pedicini A, Pezzella G, Valori V, Galetta D, Contillo A, Prete F. Biochemical modulation of fluorouracil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Gruppo Oncologico dell' Italia Meridionale (GOIM). Anticancer Res. 1994 Sep-Oct;14(5B):2157-62.</citation>
    <PMID>7840516</PMID>
  </reference>
  <reference>
    <citation>Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000 Sep 28;343(13):905-14.</citation>
    <PMID>11006366</PMID>
  </reference>
  <reference>
    <citation>Scheithauer W, Kornek GV, Raderer M, SchÃ¼ll B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003 Apr 1;21(7):1307-12.</citation>
    <PMID>12663719</PMID>
  </reference>
  <reference>
    <citation>Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000 Mar 25;355(9209):1041-7. Erratum in: Lancet 2000 Apr 15;355(9212):1372.</citation>
    <PMID>10744089</PMID>
  </reference>
  <reference>
    <citation>Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, LÃ©vi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000 Jan;18(1):136-47.</citation>
    <PMID>10623704</PMID>
  </reference>
  <reference>
    <citation>Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.</citation>
    <PMID>15175435</PMID>
  </reference>
  <reference>
    <citation>Van Cutsem E, KÃ¶hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, PintÃ©r T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.</citation>
    <PMID>19339720</PMID>
  </reference>
  <reference>
    <citation>Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4.</citation>
    <PMID>15570210</PMID>
  </reference>
  <reference>
    <citation>Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1.</citation>
    <PMID>12049538</PMID>
  </reference>
  <reference>
    <citation>Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51.</citation>
    <PMID>15570209</PMID>
  </reference>
  <reference>
    <citation>Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004 Mar;15(3):460-6.</citation>
    <PMID>14998849</PMID>
  </reference>
  <reference>
    <citation>Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005 Jun;200(6):845-53.</citation>
    <PMID>15922194</PMID>
  </reference>
  <reference>
    <citation>DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002 Feb;22(1):27-42. Review.</citation>
    <PMID>11928077</PMID>
  </reference>
  <reference>
    <citation>Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007 Mar;94(3):274-86. Review.</citation>
    <PMID>17315288</PMID>
  </reference>
  <reference>
    <citation>Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol. 1993 Dec;11(12):2386-90.</citation>
    <PMID>8246027</PMID>
  </reference>
  <reference>
    <citation>Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg. 2003 Dec;7(8):1082-8.</citation>
    <PMID>14675719</PMID>
  </reference>
  <reference>
    <citation>Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.</citation>
    <PMID>15915461</PMID>
  </reference>
  <reference>
    <citation>Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006 May 1;24(13):2065-72.</citation>
    <PMID>16648507</PMID>
  </reference>
  <reference>
    <citation>Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009 Mar;249(3):420-5. doi: 10.1097/SLA.0b013e31819a0486.</citation>
    <PMID>19247029</PMID>
  </reference>
  <reference>
    <citation>Sasaki M, Itatsu K, Minato H, Takamura H, Ohta T, Nakanuma Y. Flare-up of nonalcoholic steatohepatitis after hepatectomy resulted in hepatic failure in a patient with type 2 diabetes mellitus. Dig Dis Sci. 2007 Dec;52(12):3473-6. Epub 2007 Apr 3.</citation>
    <PMID>17404845</PMID>
  </reference>
  <reference>
    <citation>Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 May;37(5):1202-19. Review. Erratum in: Hepatology. 2003 Aug;38(2):536.</citation>
    <PMID>12717402</PMID>
  </reference>
  <reference>
    <citation>Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul;129(1):113-21.</citation>
    <PMID>16012941</PMID>
  </reference>
  <reference>
    <citation>Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002 Jul;123(1):134-40.</citation>
    <PMID>12105842</PMID>
  </reference>
  <reference>
    <citation>Pessaux P, Panaro F, Casnedi S, Zeca I, Marzano E, Bachellier P, Jaeck D, Chenard MP. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol. 2010 Jun;36(6):575-82. doi: 10.1016/j.ejso.2010.04.010. Epub 2010 May 7.</citation>
    <PMID>20452168</PMID>
  </reference>
  <reference>
    <citation>Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1.</citation>
    <PMID>10200776</PMID>
  </reference>
  <reference>
    <citation>KÃ¶hne CH, Van Cutsem E, Wils J, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc AmSocClinOncol 2003;22:Abstract 1018</citation>
  </reference>
  <reference>
    <citation>Tournigand C, Louvet C, Quinaux E et al. FOLFIRI followed by FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol 2001;20:124a (Abstract 494)</citation>
  </reference>
  <reference>
    <citation>Tournigand C, AndrÃ© T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15;22(2):229-37. Epub 2003 Dec 2.</citation>
    <PMID>14657227</PMID>
  </reference>
  <reference>
    <citation>de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug;18(16):2938-47.</citation>
    <PMID>10944126</PMID>
  </reference>
  <reference>
    <citation>Eric Van Cutsem et al., Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer - the influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial, ASCO GI 2010, Abstract # 281</citation>
  </reference>
  <reference>
    <citation>Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74.</citation>
    <PMID>11602624</PMID>
  </reference>
  <reference>
    <citation>Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000 Sep;6(9):998-1003.</citation>
    <PMID>10973319</PMID>
  </reference>
  <reference>
    <citation>Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005 May;100(5):1082-90.</citation>
    <PMID>15842582</PMID>
  </reference>
  <reference>
    <citation>Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004 Mar 1;19(5):537-44.</citation>
    <PMID>14987322</PMID>
  </reference>
  <reference>
    <citation>Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166. Review.</citation>
    <PMID>17253544</PMID>
  </reference>
  <reference>
    <citation>Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S, Bhansali A. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol. 2007 Oct-Dec;6(4):222-6.</citation>
    <PMID>18007551</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>March 7, 2014</last_update_submitted>
  <last_update_submitted_qc>March 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver injury</keyword>
  <keyword>steatosis</keyword>
  <keyword>KRAS-Wild-Type</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>metformin</keyword>
  <keyword>placebo</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

